Want to see HK:2216 full AI Analyst Report?
Top Page
Broncus Holding Corp.
(2216)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$0.59
▼(-75.13% Downside)
Action:Reiterated
Date:07/09/26
The score is driven primarily by very weak fundamentals—sharp revenue deterioration, ongoing losses, and persistent negative operating/free cash flow—tempered only by a low-leverage balance sheet. Technical indicators also point to a continued downtrend (price below key moving averages and negative MACD). Valuation is not supportive due to negative earnings and no dividend yield provided.
Positive Factors
Low leverage and positive equity
Extremely low leverage reduces refinancing pressure and preserves financial flexibility while the company works through operating weakness. Positive equity provides a stronger capital base than in 2020, potentially allowing management more time to stabilize the business and fund necessary commercial initiatives.
Negative Factors
Severe revenue deterioration
A revenue collapse of this magnitude signals a major setback in commercial traction and weakens the foundation for future operating leverage. Persistently reduced sales can limit investment in product development, market access, and commercialization, making recovery dependent on rebuilding demand over multiple periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and positive equity
Extremely low leverage reduces refinancing pressure and preserves financial flexibility while the company works through operating weakness. Positive equity provides a stronger capital base than in 2020, potentially allowing management more time to stabilize the business and fund necessary commercial initiatives.
Read all positive factors
Broncus Holding Corp. (2216) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$327.82M
Dividend YieldN/A
Average Volume (3M)287.07K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees195
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.04
Shares Outstanding528,737,060
10 Day Avg. Volume318,400
30 Day Avg. Volume287,066
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)0.99
Price to Sales (P/S)850.01
P/FCF Ratio-14.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$16.96M
Broncus Holding Corp. Business Overview & Revenue Model
Company Description
Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other internation...
How the Company Makes Money
null...
Broncus Holding Corp. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
23
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.80M | 174.00K | 8.13M | 10.26M | 9.41M | 10.89M |
| Gross Profit | -2.43M | -917.00K | 6.14M | 7.23M | 7.32M | 8.74M |
| EBITDA | -20.30M | -22.68M | -18.96M | -25.06M | -30.58M | -233.31M |
| Net Income | -18.22M | -17.88M | -15.30M | -28.09M | -28.04M | -236.18M |
Balance Sheet | ||||||
| Total Assets | 150.57M | 156.11M | 175.90M | 195.81M | 221.94M | 252.81M |
| Cash, Cash Equivalents and Short-Term Investments | 99.28M | 69.24M | 139.11M | 156.88M | 187.91M | 227.21M |
| Total Debt | 244.97K | 16.00K | 318.00K | 2.35M | 1.47M | 1.95M |
| Total Liabilities | 7.70M | 6.17M | 6.42M | 10.44M | 8.48M | 10.39M |
| Stockholders Equity | 142.85M | 149.94M | 169.48M | 185.37M | 213.46M | 242.42M |
Cash Flow | ||||||
| Free Cash Flow | -9.36M | -10.04M | -10.32M | -26.84M | -31.81M | -33.38M |
| Operating Cash Flow | -9.14M | -10.00M | -10.00M | -26.13M | -30.95M | -31.49M |
| Investing Cash Flow | 5.55M | -877.29K | -25.91M | 5.49M | -87.57M | -1.75M |
| Financing Cash Flow | -2.82M | -4.60M | -1.02M | -1.46M | -572.00K | 241.82M |
Broncus Holding Corp. Technical Analysis
Negative
2.36
Price Trends
0.65
Negative
0.80
Negative
1.38
Negative
Market Momentum
>-0.01
Negative
46.39
Neutral
36.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2216, the sentiment is Negative. The current price of 2.36 is above the 20-day moving average (MA) of 0.63, above the 50-day MA of 0.65, and above the 200-day MA of 1.38, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.39 is Neutral, neither overbought nor oversold. The STOCH value of 36.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2216.
Broncus Holding Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$448.87M | 4.47 | 13.95% | 6.92% | 10.95% | 9.26% | |
59 Neutral | HK$2.82B | 27.86 | 4.06% | ― | 94.80% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$11.65B | 31.24 | 6.07% | 0.06% | -3.62% | ― | |
42 Neutral | HK$269.06M | -2.95 | -19.46% | ― | 4.35% | 43.23% | |
41 Neutral | HK$327.82M | -2.10 | -12.45% | ― | ― | ― | |
39 Underperform | HK$21.97B | -75.52 | -52.78% | ― | 114.97% | 63.21% |
* Healthcare Sector Average
HK:2216
Broncus Holding Corp.
0.62
-2.75
-81.70%
HK:0853
MicroPort Scientific
6.08
-7.84
-56.33%
HK:1612
Vincent Medical Holdings Limited
0.67
-0.33
-32.87%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
6.66
-1.97
-22.83%
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
21.18
-7.74
-26.76%
HK:2297
Rainmed Medical Limited
0.17
-0.15
-48.13%
Broncus Holding Corp. Corporate Events
Broncus Holding Delays Circular on Major Share Acquisition to September
Aug 31, 2026
Broncus Holding Corporation has announced a further delay in sending a shareholder circular related to a major transaction involving the additional acquisition of shares in a target company, first disclosed in March 2026. The company now expects t...
Broncus Holding to Publish Unaudited Interim Results for First Half of 2026
Aug 27, 2026
Broncus Holding Corporation has released its unaudited interim results for the six months ended June 30, 2026, fulfilling disclosure requirements of the Hong Kong listing rules. The full interim report, including financial highlights, business upd...
Broncus Holding Sets Board Meeting to Approve 2026 Interim Results
Aug 17, 2026
Broncus Holding Corporation has scheduled a board meeting for August 27, 2026, to review and approve the unaudited interim results for the six months ended June 30, 2026. The planned publication of these interim results will provide investors and ...
Broncus Wins EU MDR CE Mark for BroncTru Lung Catheter, Expanding Global Reach
Jul 27, 2026
Broncus Holding Corp. announced that its independently developed BroncTru disposable transbronchial puncture dilation catheter has obtained EU Medical Device Regulation CE marking, a key certification for entry into the European medical device mar...
Broncus Announces Further Delay in Circular for Major Share Acquisition
Jun 30, 2026
Broncus Holding Corporation has notified investors of a further delay in issuing a shareholder circular related to a major transaction involving additional acquisition of shares in a target company. The circular, originally expected by June 30, 20...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.